Literature DB >> 11962752

Tetranectin expression in gastric adenocarcinomas.

D L Arvanitis1, E F Kamper, L Kopeikina, A Stavridou, M N Sgantzos, V Kallioras, E Athanasiou, P Kanavaros.   

Abstract

AIMS: The aim was to analyze the immunohistochemical localization of tetranectin in gastric adenocarcinomas and the adjacent tissues of the wall of the stomach. METHODS AND
RESULTS: Forty cases of gastric adenocarcinomas were stained by the indirect immunoperoxidase method. Of the ten cases of mucinous signet ring cell carcinomas 5 showed high, 3 moderate and 2 low tetranectin expression. Of the ten cases of well-differentiated intestinal type adenocarcinomas (ITA) 4 showed moderate regional, 3 low regional and 3 negative tetranectin expression. Of the ten cases of moderately-differentiated ITA 3 showed moderate regional, 4 low regional and 3 negative tetranectin expression. Of the ten cases of poorly-differentiated ITA 4 showed focal low and 6 negative tetranectin expression. Overall, the mucinous signet ring carcinomas showed significantly higher tetranectin expression compared to ITA (chi2 = 3.95, p<0.05). In contrast, no significant relationship was found between tetranectin expression and the degree of differentiation in ITA (chi2 = 2.5, p>0.05). In all cases, the perineoplastic desmoplastic reactive stroma showed high expression of tetranectin intra- and extracellularly. The mast cells and goblet cells in the areas of intestinal metaplasia showed high tetranectin expression.
CONCLUSIONS: This study shows that: a) tetranectin is produced and deposited extracellularly in the desmoplastic peritumoral stroma of infiltrating gastric adenocarcinomas; b) tetranectin is more highly expressed by the mucinous signet ring cell carcinomas compared to ITA; and c) the amount of tetranectin produced by the ITA is unrelated with the degree of tumor differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11962752     DOI: 10.14670/HH-17.471

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

2.  Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

Authors:  A Brunner; C Ensinger; M Christiansen; S Heiss; I Verdorfer; G Mikuz; A Tzankov
Journal:  Virchows Arch       Date:  2007-04-13       Impact factor: 4.064

3.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

4.  Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours.

Authors:  Bartosz Wojtas; Aleksandra Pfeifer; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Agnieszka Czarniecka; Aleksandra Kukulska; Markus Eszlinger; Thomas Musholt; Tomasz Stokowy; Michal Swierniak; Ewa Stobiecka; Ewa Chmielik; Dagmara Rusinek; Tomasz Tyszkiewicz; Monika Halczok; Steffen Hauptmann; Dariusz Lange; Michal Jarzab; Ralf Paschke; Barbara Jarzab
Journal:  Int J Mol Sci       Date:  2017-06-02       Impact factor: 5.923

5.  iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis.

Authors:  Bo Yan; Binshen Chen; Shaoju Min; Yubo Gao; Yiming Zhang; Peng Xu; Chaoming Li; Jiasheng Chen; Guangheng Luo; Chunxiao Liu
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

6.  CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.

Authors:  Xing-Wei Xie; Shan-Shan Jiang; Xiang Li
Journal:  Front Mol Biosci       Date:  2021-01-20

7.  Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.

Authors:  Luis Bujanda; Cristina Sarasqueta; Angel Cosme; Elizabeth Hijona; José M Enríquez-Navascués; Carlos Placer; Eloisa Villarreal; Marta Herreros-Villanueva; María D Giraldez; Meritxell Gironella; Francesc Balaguer; Antoni Castells
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.